SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease

Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce cardiovascular events in humans with type 2 diabetes (T2D); however, the underlying mechanism remains unclear. Activation of the NLR family, pyrin domain-containing 3 (NLRP3) inflammasome and subsequent interleukin (IL)-1β release induces athe...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, So Ra, Lee, Sang-Guk, Kim, Soo Hyun, Kim, Jin Hee, Choi, Eunhye, Cho, Wonhee, Rim, John Hoon, Hwang, Inhwa, Lee, Chan Joo, Lee, Minyoung, Oh, Chang-Myung, Jeon, Justin Y., Gee, Heon Yung, Kim, Jeong-Ho, Lee, Byung-Wan, Kang, Eun Seok, Cha, Bong-Soo, Lee, Myung-Shik, Yu, Je-Wook, Cho, Jin Won, Kim, Jung-Sun, Lee, Yong-ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195385/
https://www.ncbi.nlm.nih.gov/pubmed/32358544
http://dx.doi.org/10.1038/s41467-020-15983-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195385/
https://www.ncbi.nlm.nih.gov/pubmed/32358544
http://dx.doi.org/10.1038/s41467-020-15983-6

Ejemplares similares